Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Genetic variation associated with cardiovascular risk in autoimmune diseases

  • Perrotti, P.P.
  • Aterido, A.
  • Fernández-Nebro, A.
  • Cañete, J.D.
  • Ferrándiz, C.
  • Tornero, J.
  • Gisbert, J.P.
  • Domènech, E.
  • Fernández-Gutiérrez, B.
  • Gomollón, Fernando
  • García-Planella, E.
  • Fernández, E.
  • Sanmartí, R.
  • Gratacós, J.
  • Martínez-Taboada, V.M.
  • Rodríguez-Rodríguez, L.
  • Palau, N.
  • Tortosa, R.
  • Corbeto, M.L.
  • Lasanta, M.L.
  • Marsal, S.
  • Julià, A.
Autoimmune diseases have a higher prevalence of cardiovascular events compared to the general population. The objective of this study was to investigate the genetic basis of cardiovascular disease (CVD) risk in autoimmunity. We analyzed genome-wide genotyping data from 6, 485 patients from six autoimmune diseases that are associated with a high socioeconomic impact. First, for each disease, we tested the association of established CVD risk loci. Second, we analyzed the association of autoimmune disease susceptibility loci with CVD. Finally, to identify genetic patterns associated with CVD risk, we applied the cross-phenotype meta-analysis approach (CPMA) on the genome-wide data. A total of 17 established CVD risk loci were significantly associated with CVD in the autoimmune patient cohorts. From these, four loci were found to have significantly different genetic effects across autoimmune diseases. Six autoimmune susceptibility loci were also found to be associated with CVD risk. Genome-wide CPMA analysis identified 10 genetic clusters strongly associated with CVD risk across all autoimmune diseases. Two of these clusters are highly enriched in pathways previously associated with autoimmune disease etiology (TNFa and IFN¿ cytokine pathways). The results of this study support the presence of specific genetic variation associated with the increase of CVD risk observed in autoimmunity.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

  • González-Serna, D.
  • Ochoa, E.
  • López-Isac, E.
  • Julià, A.
  • Degenhardt, F.
  • Ortego-Centeno, N.
  • Radstake, T.R.D.J.
  • Franke, A.
  • Marsal, S.
  • Mayes, M.D.
  • Martín, J.
  • Márquez, A.
  • Assassi, S.
  • Zhou, X.
  • Tan, F.K.
  • Arnett, F.C.
  • Reveille, J.D.
  • Gorlova, O.
  • Chen, W.V.
  • Ying, J.
  • Gregersen, P.K.
  • Lee, A.T.
  • Voskuyl, A.E.
  • de Vries-Bouwstra, J.
  • Magro-Checa, C.
  • Broen, J.
  • Koeleman, B.P.C.
  • Simeón, C.P.
  • Fonollosa, V.
  • Guillén, A.
  • Carreira, P.
  • Castellví, I.
  • González-Gay, M.A.
  • Ríos, R.
  • Callejas-Rubio, J.L.
  • Vargas-Hitos, J.A.
  • García-Portales, R.
  • Camps, M.T.
  • Fernández-Nebro, A.
  • González-Escribano, M.F.
  • García-Hernández, F.J.
  • Castillo, M.J.
  • Aguirre, M.Á.
  • Gómez-Gracia, I.
  • Rodríguez-Rodríguez, L.
  • Fernández-Gutiérrez, B.
  • de la Peña, P.G.
  • Vicente, E.
  • Andreu, J.L.
  • Fernández de Castro, M.
  • López-Longo, F.J.
  • Martínez, L.
  • Espinosa, G.
  • Tolosa, C.
  • Pros, A.
  • Rodríguez-Carballeira, M.
  • Narváez, F.J.
  • Rubio-Rivas, M.
  • Ortiz-Santamaría, V.
  • Madroñero, A.B.
  • Díaz, B.
  • Trapiella, L.
  • Sousa, A.
  • Egurbide, M.V.
  • Fanlo-Mateo, P.
  • Sáez-Comet, L.
  • Díaz-González, F.
  • Hernández, V.
  • Beltrán, E.
  • Román-Ivorra, J.A.
  • Grau, E.
  • Alegre-Sancho, J.J.
  • Blanco-García, F.J.
  • Oreiro, N.
  • Freire, M.
  • Balsa, A.
  • Ortiz, A.M.
  • Hunzelmann, N.
  • Riemekasten, G.
  • Distler, J.H.W.
  • Witte, T.
  • Airó, P.
  • Beretta, L.
  • Santaniello, A.
  • Bellocchi, C.
  • Lunardi, C.
  • Moroncini, G.
  • Gabrielli, A.
  • Scleroderma, Genetic, Consortium
Genome-wide association studies (GWASs) have identified a number of genetic risk loci associated with systemic sclerosis (SSc) and Crohn’s disease (CD), some of which confer susceptibility to both diseases. In order to identify new risk loci shared between these two immune-mediated disorders, we performed a cross-disease meta-analysis including GWAS data from 5, 734 SSc patients, 4, 588 CD patients and 14, 568 controls of European origin. We identified 4 new loci shared between SSc and CD, IL12RB2, IRF1/SLC22A5, STAT3 and an intergenic locus at 6p21.31. Pleiotropic variants within these loci showed opposite allelic effects in the two analysed diseases and all of them showed a significant effect on gene expression. In addition, an enrichment in the IL-12 family and type I interferon signaling pathways was observed among the set of SSc-CD common genetic risk loci. In conclusion, through the first cross-disease meta-analysis of SSc and CD, we identified genetic variants with pleiotropic effects on two clinically distinct immune-mediated disorders. The fact that all these pleiotropic SNPs have opposite allelic effects in SSc and CD reveals the complexity of the molecular mechanisms by which polymorphisms affect diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis

  • Ávila, Gabriela
  • Tornero, Jesús
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Blanco, Francisco
  • González-Alvaro, Isidoro
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Maymó, Joan
  • Alperiz, Mercedes
  • Fernández-Gutiérrez, Benjamín
  • Olivé Marqués, Alejandro|||0000-0002-6707-8043
  • Corominas, Hèctor|||0000-0002-7738-6787
  • Erra Duran, Alba|||0000-0001-7806-1098
  • Aterido, Adrià|||0000-0003-1810-410X
  • López Lasanta, María|||0000-0002-8462-8406
  • Tortosa, Raül
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • Marsal, Sara|||0000-0001-5515-3854
Objective: Anti-TNF therapies have been highly efficacious in the management of rheumatoid arthritis (RA), but 25-30% of patients do not show a significant clinical response. There is increasing evidence that genetic variation at the Fc receptor FCGR2A is associated with the response to anti-TNF therapy. We aimed to validate this genetic association in a patient cohort from the Spanish population, and also to identify new genes functionally related to FCGR2A that are also associated with anti-TNF response. Methods: A total of 348 RA patients treated with an anti-TNF therapy were included and genotyped for FCGR2A polymorphism rs1081274. Response to therapy was determined at 12 weeks, and was tested for association globally and independently for each anti-TNF drug (infliximab, etanercept and adalimumab). Using gene expression profiles from macrophages obtained from synovial fluid of RA patients, we searched for genes highly correlated with FCGR2A expression. Tag SNPs were selected from each candidate gene and tested for association with the response to therapy. Results: We found a significant association between FCGR2A and the response to adalimumab (P=0.022). Analyzing the subset of anti-CCP positive RA patients (78%), we also found a significant association between FCGR2A and the response to infliximab (P=0.035). DHX32 and RGS12 were the most consistently correlated genes with FCGR2A expression in RA synovial fluid macrophages (P<0.001). We found a significant association between the genetic variation at DHX32 (rs12356233, corrected P=0.019) and a nominally significant association between RGS12 and the response to adalimumab (rs4690093, uncorrected P=0.040). In the anti-CCP positive group of patients, we also found a nominally significant association between RGS12 and the response to infliximab (rs2857859, uncorrected P=0.042). Conclusions: In the present study we have validated the FCGR2A association in an independent population, and we have identified new genes associated with the response to anti-TNF therapy in RA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Urine metabolome profiling of immune-mediated inflammatory diseases

  • Alonso, Arnald
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • Vinaixa, Maria
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Ferrándiz, Carlos|||0000-0001-9030-8399
  • Tornero, Jesús
  • P. Gisbert, Javier|||0000-0003-2090-3445
  • Nos Mateu, Pilar
  • Gutiérrez Casbas, Ana|||0000-0002-5460-4139
  • Puig Sanz, Lluís|||0000-0001-6083-0952
  • González-Alvaro, Isidoro
  • Pinto-Tasende, José A.
  • Blanco, Ricardo|||0000-0003-2344-2285
  • Rodríguez, Miguel A.
  • Beltran, Antoni
  • Correig, Xavier|||0000-0002-6902-3054
  • Marsal, Sara|||0000-0001-5515-3854
BACKGROUND: Immune-mediated inflammatory diseases (IMIDs) are a group of complex and prevalent diseases where disease diagnostic and activity monitoring is highly challenging. The determination of the metabolite profiles of biological samples is becoming a powerful approach to identify new biomarkers of clinical utility. In order to identify new metabolite biomarkers of diagnosis and disease activity, we have performed the first large-scale profiling of the urine metabolome of the six most prevalent IMIDs: rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis. METHODS: Using nuclear magnetic resonance, we analyzed the urine metabolome in a discovery cohort of 1210 patients and 100 controls. Within each IMID, two patient subgroups were recruited representing extreme disease activity (very high vs. very low). Metabolite association analysis with disease diagnosis and disease activity was performed using multivariate linear regression in order to control for the effects of clinical, epidemiological, or technical variability. After multiple test correction, the most significant metabolite biomarkers were validated in an independent cohort of 1200 patients and 200 controls. RESULTS: In the discovery cohort, we identified 28 significant associations between urine metabolite levels and disease diagnosis and three significant metabolite associations with disease activity (P FDR < 0.05). Using the validation cohort, we validated 26 of the diagnostic associations and all three metabolite associations with disease activity (P FDR < 0.05). Combining all diagnostic biomarkers using multivariate classifiers we obtained a good disease prediction accuracy in all IMIDs and particularly high in inflammatory bowel diseases. Several of the associated metabolites were found to be commonly altered in multiple IMIDs, some of which can be considered as hub biomarkers. The analysis of the metabolic reactions connecting the IMID-associated metabolites showed an over-representation of citric acid cycle, phenylalanine, and glycine-serine metabolism pathways. CONCLUSIONS: This study shows that urine is a source of biomarkers of clinical utility in IMIDs. We have found that IMIDs show similar metabolic changes, particularly between clinically similar diseases and we have found, for the first time, the presence of hub metabolites. These findings represent an important step in the development of more efficient and less invasive diagnostic and disease monitoring methods in IMIDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic variation associated with cardiovascular risk in autoimmune diseases

  • Perrotti, Pedro P.
  • Aterido, Adrià|||0000-0003-1810-410X
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Ferrándiz, Carlos|||0000-0001-9030-8399
  • Tornero, Jesús
  • P. Gisbert, Javier|||0000-0003-2090-3445
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Fernández-Gutiérrez, Benjamín
  • Gomollón, Fernando|||0000-0003-0076-3529
  • García-Planella, Esther|||0000-0002-4325-0697
  • Fernández, Emilia
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Gratacós, Jordi|||0000-0003-4007-4103
  • Martínez-Taboada, Víctor Manuel
  • Rodríguez-Rodríguez, Luís
  • Palau, Núria
  • Tortosa, Raúl
  • Corbeto, Mireia L.
  • Lasanta, María L.
  • Marsal, Sara|||0000-0001-5515-3854
  • Julià Cano, Antonio|||0000-0001-6064-3620
Autoimmune diseases have a higher prevalence of cardiovascular events compared to the general population. The objective of this study was to investigate the genetic basis of cardiovascular disease (CVD) risk in autoimmunity. We analyzed genome-wide genotyping data from 6,485 patients from six autoimmune diseases that are associated with a high socioeconomic impact. First, for each disease, we tested the association of established CVD risk loci. Second, we analyzed the association of autoimmune disease susceptibility loci with CVD. Finally, to identify genetic patterns associated with CVD risk, we applied the crossphenotype meta-analysis approach (CPMA) on the genome-wide data. A total of 17 established CVD risk loci were significantly associated with CVD in the autoimmune patient cohorts. From these, four loci were found to have significantly different genetic effects across autoimmune diseases. Six autoimmune susceptibility loci were also found to be associated with CVD risk. Genome-wide CPMA analysis identified 10 genetic clusters strongly associated with CVD risk across all autoimmune diseases. Two of these clusters are highly enriched in pathways previously associated with autoimmune disease etiology (TNFα and IFNγ cytokine pathways). The results of this study support the presence of specific genetic variation associated with the increase of CVD risk observed in autoimmunity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis

  • Aterido, Adrià|||0000-0003-1810-410X
  • Cañete, Juan D.|||0000-0003-2606-0573
  • Tornero, Jesús
  • Blanco-García, F.J.|||0000-0001-9821-7635
  • Fernández-Gutiérrez, Benjamín
  • Pérez-García, Carolina|||0000-0002-6695-6406
  • Alperi-López, Mercedes
  • Olivé Marqués, Alejandro|||0000-0002-6707-8043
  • Corominas, Hèctor|||0000-0002-7738-6787
  • Martínez-Taboada, Víctor
  • González, Isidoro
  • Fernández-Nebro, Antonio|||0000-0002-2962-9844
  • Erra Duran, Alba|||0000-0001-7806-1098
  • López Lasanta, María|||0000-0002-8462-8406
  • López-Corbeto, Mireia|||0000-0003-1166-1456
  • Palau, Núria
  • Marsal, Sara|||0000-0001-5515-3854
  • Julià Cano, Antonio|||0000-0001-6064-3620
Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sampling time-dependent artifacts in single-cell genomics studies

  • Massoni-Badosa, Ramon
  • Iacono, G.
  • Moutinho, Catia|||0000-0003-3885-0847
  • Kulis, M.
  • Palau, Núria
  • Marchese, Domenica|||0000-0002-3036-4580
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Rodriguez-Esteban, G.
  • Marsal, Sara|||0000-0001-5515-3854
  • Aymerich, Marta
  • Colomer, Dolors|||0000-0001-7486-8484
  • Campo, Elias|||0000-0001-9850-9793
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • Martin-Subero, Jose Ignacio|||0000-0001-8809-5195
  • Heyn, Holger|||0000-0002-3276-1889
Robust protocols and automation now enable large-scale single-cell RNA and ATAC sequencing experiments and their application on biobank and clinical cohorts. However, technical biases introduced during sample acquisition can hinder solid, reproducible results, and a systematic benchmarking is required before entering large-scale data production. Here, we report the existence and extent of gene expression and chromatin accessibility artifacts introduced during sampling and identify experimental and computational solutions for their prevention.